Molecular Testing Guideline for Selection of Lung Cancer Patients for EGFR and ALK Tyrosine Kinase Inhibitors
about
Precision medicine in NSCLC and pathology: how does ALK fit in the pathway?Somatic DNA mutation analysis in targeted therapy of solid tumoursThe Utilization of Cytologic Fine-Needle Aspirates of Lung Cancer for Molecular Diagnostic TestingThe role of the immune system in non-small cell lung carcinoma and potential for therapeutic interventionEpidermal growth factor receptor inhibitors: coming of ageNext generation sequencing techniques in liquid biopsy: focus on non-small cell lung cancer patientsMolecular Diagnostics for Precision Medicine in Colorectal Cancer: Current Status and Future PerspectiveTesting for ROS1 in non-small cell lung cancer: a review with recommendationsUnravelling signal escape through maintained EGFR activation in advanced non-small cell lung cancer (NSCLC): new treatment optionsEpidermal growth factor receptor in non-small cell lung cancerConcomitant EML4-ALK rearrangement and EGFR mutation in non small cell lung cancer patients: A literature review of 100 cases.Genomic sequencing: assessing the health care system, policy, and big-data implications.Improving molecular testing and personalized medicine in non-small-cell lung cancer in OntarioEpidermal growth factor receptor mutations and anaplastic lymphoma kinase rearrangements in lung cancer with nodular ground-glass opacity.ALK-rearrangements and testing methods in non-small cell lung cancer: a reviewDetection of gene rearrangements in targeted clinical next-generation sequencing.Effective ultra-low doses of erlotinib in patients with EGFR sensitising mutationEconomic Impact of Tissue Testing and Treatments of Metastatic NSCLC in the Era of Personalized MedicineProspective enterprise-level molecular genotyping of a cohort of cancer patients.The relevance of external quality assessment for molecular testing for ALK positive non-small cell lung cancer: results from two pilot rounds show room for optimization.AZD9291 in EGFR-mutant advanced non-small-cell lung cancer patients.Diffusion of molecular diagnostic lung cancer tests: a survey of german oncologistsEmerging understanding of multiscale tumor heterogeneitySuitability of surgical tumor tissues, biopsy, or cytology samples for epidermal growth factor receptor mutation testing in non-small cell lung carcinoma based on chinese population.Clinical validation of a PCR assay for the detection of EGFR mutations in non-small-cell lung cancer: retrospective testing of specimens from the EURTAC trial.The use of a two-tiered testing strategy for the simultaneous detection of small EGFR mutations and EGFR amplification in lung cancer.Fluorescence in situ hybridization, immunohistochemistry, and next-generation sequencing for detection of EML4-ALK rearrangement in lung cancer.A phase IIa randomized, double-blind trial of erlotinib in inhibiting epidermal growth factor receptor signaling in aberrant crypt foci of the colorectumMolecular methods for somatic mutation testing in lung adenocarcinoma: EGFR and beyondMulti-institutional Oncogenic Driver Mutation Analysis in Lung Adenocarcinoma: The Lung Cancer Mutation Consortium Experience.Prognostic Value of Beta-Tubulin-3 and c-Myc in Muscle Invasive Urothelial Carcinoma of the Bladder.Factors affecting the success of next-generation sequencing in cytology specimens.Rapid targeted somatic mutation analysis of solid tumors in routine clinical diagnosticsThe Contrasting Role of p16Ink4A Patterns of Expression in Neuroendocrine and Non-Neuroendocrine Lung Tumors: A Comprehensive Analysis with Clinicopathologic and Molecular CorrelationsClinical Validation and Implementation of a Targeted Next-Generation Sequencing Assay to Detect Somatic Variants in Non-Small Cell Lung, Melanoma, and Gastrointestinal Malignancies.Building a Robust Tumor Profiling Program: Synergy between Next-Generation Sequencing and Targeted Single-Gene TestingWords matter: distinguishing "personalized medicine" and "biologically personalized therapeutics"Inconsistent results in the analysis of ALK rearrangements in non-small cell lung cancerClinical Application of Picodroplet Digital PCR Technology for Rapid Detection of EGFR T790M in Next-Generation Sequencing Libraries and DNA from Limited Tumor Samples.Concurrent oncogene mutation profile in Chinese patients with stage Ib lung adenocarcinoma
P2860
Q26738390-D5D07013-A61C-4617-B3F1-012E3090E48CQ26770324-4E7CADBB-984F-4E00-A8F9-BA252FA1FAC7Q26824315-B879C3C0-648A-4BB0-9D49-5D1C204756A9Q27024781-7A761B6D-3EA7-4100-B40E-4A6D73A91901Q27030769-D3D39E90-D710-4D3C-8BD8-4BD3B9A2A099Q28067439-545137FC-8015-4039-B218-658F3B452440Q28070038-918E95E6-326B-4043-9442-827AC41A8307Q28070062-B0F8837D-68BE-4E12-9E9E-B3E92C8DA43CQ28075291-318244FB-DC05-47F6-B04A-82D5123BBD01Q28088636-714BC561-91E1-424F-A5C4-8FB73E56AE02Q30234436-2E80B472-E06B-4AB5-A2C5-00C985A0B30DQ30835712-744B1779-956D-4466-AB69-3160D35BE113Q33611088-E861B92A-2290-43B4-96E9-CFC8E4E417A0Q33617464-915A4D0B-7C64-44D1-8EDE-F71255C25A9AQ33776835-17CF253D-A7C3-4FDD-89D8-F964EEF36A68Q33833183-B0A28A70-9E7E-4A73-85A7-41480F60AB03Q33955857-EF744793-DB80-4658-918C-DAC68526FB4DQ34219452-6E6992BC-37AF-4CD2-829F-7A7051416FCAQ34409739-F0739F80-5BE3-436D-BC5F-45E8081BD594Q34489837-4AAF1DC5-3B6D-46D3-B779-58C9ECBF3857Q34497467-D277138F-4698-4428-A0D5-53BDDA8B3E27Q34608778-2A88185D-36D1-42D3-A3E3-0A1A0306D0FDQ34730000-39EA4F85-C034-4E73-A7E9-0A91D0755DC1Q35028752-D95D99D4-D073-4A84-AD96-5264C9C65AB8Q35107524-1FAB076E-2DE5-48B9-AC6D-3519FEE45132Q35125795-95CAC122-B266-4D9A-99D9-0CDD56ECE43BQ35151114-C6488E41-03BC-49A2-8314-0A1523AFEFC1Q35163569-D3D9A79E-D35A-443D-A30E-BC79CA92CE3DQ35256622-63B9C4CF-C3FA-43F5-8D4F-31B2D4B1C4FAQ35541778-51E5267A-A562-44BD-AB6F-FAB7DC9736D8Q35653741-9E770388-0A57-4728-ADFF-5E3B78837DA6Q35730088-C7504E66-18AE-43CF-B3F1-4415C5DB28E4Q35798726-011BE23F-90B8-4C56-BBB6-B78A48AB3FC8Q35870560-1B2F9F6F-AA1F-4458-BC20-F3722F4D2319Q35901968-72E2B46D-929B-474E-951E-1C8428F7CBB9Q35979104-018964EE-7BC1-44EA-BC90-E3C5C9EEF35EQ36057745-4E9D6DA3-5002-4F23-8834-5981F951709EQ36096398-898E349D-6165-4C42-8AA0-BD1D44DB54EEQ36134160-39E7B750-BC03-413D-BCD9-602070DFBEE9Q36151764-133CCC5A-A581-48FB-9C2B-EE081E25A43F
P2860
Molecular Testing Guideline for Selection of Lung Cancer Patients for EGFR and ALK Tyrosine Kinase Inhibitors
description
article
@en
im Juli 2013 veröffentlichter wissenschaftlicher Artikel
@de
wetenschappelijk artikel
@nl
наукова стаття, опублікована в липні 2013
@uk
name
Molecular Testing Guideline fo ...... ALK Tyrosine Kinase Inhibitors
@en
Molecular Testing Guideline fo ...... ALK Tyrosine Kinase Inhibitors
@nl
type
label
Molecular Testing Guideline fo ...... ALK Tyrosine Kinase Inhibitors
@en
Molecular Testing Guideline fo ...... ALK Tyrosine Kinase Inhibitors
@nl
prefLabel
Molecular Testing Guideline fo ...... ALK Tyrosine Kinase Inhibitors
@en
Molecular Testing Guideline fo ...... ALK Tyrosine Kinase Inhibitors
@nl
P2093
P50
P1476
Molecular Testing Guideline fo ...... ALK Tyrosine Kinase Inhibitors
@en
P2093
David J. Kwiatkowski
Dhananjay Arun Chitale
Juan-Sebastian Saldivar
Mary Beth Beasley
Neal I. Lindeman
Philip T. Cagle
Robert Brian Jenkins
Sanja Dacic
P304
P356
10.1016/J.JMOLDX.2013.03.001
P577
2013-07-01T00:00:00Z